ArticleJournal of translational internal medicine2025
Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria.
Article in Journal of translational internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Etiology-related differences in hepatic recompensation in decompensated cirrhosis under Baveno VII criteria: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Gastrointestinal bleeding risk in cirrhotic portal vein thrombosis: focus on thrombus extension to superior mesenteric vein.BMC gastroenterology · 2026Article
- [Research advances in autoimmune liver disease in 2025: toward precision regulation and personalized treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Few studies have provided real-world data on the biochemical response, risk assessment, and prognosis of patients with primary biliary cholangitis (PBC)-related decompensated cirrhosis undergoing ursodeoxycholic acid therapy. The objective of this study is to define recompensation in this patient population based on the BAVENO VII criteria. Methods: This retrospective analysis included 170 patients with cirrhosis who presented with ascites, hepatic encephalopathy, and/or variceal bleeding as their initial decompensating events at Xijing Hospital from 2006 to 2023. Events of further decompensation, liver transplantation, and liver-related death were recorded. Results: Alkaline phosphatase (ALP) had complex prognostic value in patients with PBC-related decompensated cirrhosis receiving ursodeoxycholic acid therapy. In patients with normal total bilirubin (TBIL) at the 1-year follow-up, elevated ALP was associated with poor prognosis (hazard ratio [HR]: 2.57, 95% confidence interval [CI]: 1.12-5.87, Conclusions: We defined PBC recompensation as a Model for End-Stage Liver Disease score < 10 and the absence of decompensating events from the last decompensated state for the next 12 months, aligned with the requirements of BAVENO VII for patients with PBC-related decompensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.